At the Myeloma 2015 meeting, Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, MA) provides an overview of potential new immune-based approaches for the treatment of multiple myeloma. Studies of antibodies, checkpoint inhibitors and immunomodulatory drugs are currently in evaluation in multiple clinical trials. Combination approaches are receiving interest too.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates